TY - JOUR
T1 - The possible effects of the Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 on the practice of fertility preservation in female cancer patients in Japan
AU - Kunitomi, Chisato
AU - Harada, Miyuki
AU - Sanada, Yuko
AU - Kusamoto, Akari
AU - Takai, Yasushi
AU - Furui, Tatsuro
AU - Kitagawa, Yuko
AU - Yamada, Mitsutoshi
AU - Watanabe, Chie
AU - Tsugawa, Koichiro
AU - Nishiyama, Hiroyuki
AU - Hosoi, Hajime
AU - Miyachi, Mitsuru
AU - Sugiyama, Kazuhiko
AU - Maeda, Yoshinobu
AU - Kawai, Akira
AU - Hamatani, Toshio
AU - Fujio, Keishi
AU - Suzuki, Nao
AU - Osuga, Yutaka
N1 - Funding Information:
Yoshinobu Maeda received honoraria from Kyowa‐Kirin, Bristol‐Myers Squibb, Chugai, Phizer, Celgene, Novartis, and Takeda, and research grants from Nippon Shinyaku and Chugai. The other authors declare that they have no conflict of interest.
Funding Information:
The authors thank Yumiko Muramatsu (The University of Tokyo) for her assistance with organizing the questionnaires and collecting the data. We thank also all the clinicians who participated in this study. The study was supported by Ministry of Health, Labour and Welfare Grant Number JPMH19DA1004 to Y.O.
Publisher Copyright:
© 2022 The Authors. Reproductive Medicine and Biology published by John Wiley & Sons Australia, Ltd on behalf of Japan Society for Reproductive Medicine.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Purpose: In 2017, the first guidelines for fertility preservation in cancer patients were published in Japan. However, the impact of the guidelines remains unknown. Therefore, the authors conducted a nationwide survey on cryopreservation procedures in the period from shortly before to after publication of the guidelines (2016–2019) and compared the results with our previous survey (2011–2015). The authors also surveyed reproductive specialists’ awareness of the guidelines and implementation problems. Methods: The authors sent a questionnaire to 618 assisted reproductive technology facilities certified by the Japanese Society of Obstetrics and Gynecology. Results: The authors received responses from 395 institutions (63.8%). Among them, 144 institutions conducted cryopreservation for cancer patients (vs. 126 in 2011–2015) and performed 2537 embryo or oocyte and 178 ovarian tissue cryopreservation procedures (vs. 1085 and 122, respectively). Compared with the previous period, indications were more varied and protocols for controlled ovarian stimulation were more standardized. Reproductive specialists’ interest in oncofertility was high, but many reported three main difficulties: selecting a treatment method, storing samples in the long term, and securing the necessary human resources. Conclusions: The practice of fertility preservation in cancer patients in Japan has been considerably affected by the first Japanese guidelines.
AB - Purpose: In 2017, the first guidelines for fertility preservation in cancer patients were published in Japan. However, the impact of the guidelines remains unknown. Therefore, the authors conducted a nationwide survey on cryopreservation procedures in the period from shortly before to after publication of the guidelines (2016–2019) and compared the results with our previous survey (2011–2015). The authors also surveyed reproductive specialists’ awareness of the guidelines and implementation problems. Methods: The authors sent a questionnaire to 618 assisted reproductive technology facilities certified by the Japanese Society of Obstetrics and Gynecology. Results: The authors received responses from 395 institutions (63.8%). Among them, 144 institutions conducted cryopreservation for cancer patients (vs. 126 in 2011–2015) and performed 2537 embryo or oocyte and 178 ovarian tissue cryopreservation procedures (vs. 1085 and 122, respectively). Compared with the previous period, indications were more varied and protocols for controlled ovarian stimulation were more standardized. Reproductive specialists’ interest in oncofertility was high, but many reported three main difficulties: selecting a treatment method, storing samples in the long term, and securing the necessary human resources. Conclusions: The practice of fertility preservation in cancer patients in Japan has been considerably affected by the first Japanese guidelines.
KW - assisted reproductive technology
KW - breast cancer
KW - childhood, adolescent, and young adult (CAYA)
KW - fertility preservation
KW - oncofertility
UR - http://www.scopus.com/inward/record.url?scp=85145087079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145087079&partnerID=8YFLogxK
U2 - 10.1002/rmb2.12453
DO - 10.1002/rmb2.12453
M3 - Article
AN - SCOPUS:85145087079
SN - 1445-5781
VL - 21
JO - Reproductive Medicine and Biology
JF - Reproductive Medicine and Biology
IS - 1
M1 - e12453
ER -